Nobiletin Promotes Megakaryocytic Differentiation through the MAPK/ERK-Dependent EGR1 Expression and Exerts Anti-Leukemic Effects in Human Chronic Myeloid Leukemia (CML) K562 Cells. [electronic resource]
Producer: 20210225ISSN:- 2073-4409
- Apoptosis -- drug effects
- Biomarkers, Tumor -- genetics
- Cell Cycle -- drug effects
- Cell Differentiation -- drug effects
- Cell Nucleus -- drug effects
- Cell Proliferation -- drug effects
- Early Growth Response Protein 1 -- metabolism
- Flavones -- chemistry
- Gene Expression Regulation, Leukemic -- drug effects
- Gene Ontology
- Humans
- Imatinib Mesylate -- pharmacology
- K562 Cells
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- enzymology
- MAP Kinase Signaling System -- drug effects
- Megakaryocytes -- drug effects
- RNA, Messenger -- genetics
- Up-Regulation -- drug effects
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.